Lopid (Gemfibrozil): Lipid-Modulating Agent for Atherogenic Dyslipidemia - Clinical Pharmacology Review

Let me be straight with you about Lopid. I’ve been prescribing this drug for over twenty years now, and I still remember the first time I saw it work in a way that genuinely surprised me. This isn’t some flashy new compound—it’s been around since the late 1970s—but there’s something about its particular niche in lipid management that keeps it relevant even in the era of statins and PCSK9 inhibitors.